TriSalus Life Sciences Inc (NAS:TLSI)

Q4 2025 TriSalus Life Sciences Inc Earnings Call Transcript

Mar 5, 2026 / 09:30 PM GMT

Release Date Price: $4.77 (-4.60%)

Transcript 10-K8-K

Key Points

Positve

TriSalus Life Sciences Inc (TLSI) reported strong financial results for Q4 2025, with revenues of $13.2 million, representing a 60% increase year-over-year.
The company achieved its revenue growth guidance for the 2025 fiscal year, with full-year revenues reaching $45.2 million, a 53% increase over the prior year.
TriSalus Life Sciences Inc (TLSI) successfully raised $46 million in a public offering, which was more than two times oversubscribed, indicating strong investor confidence.
The company is expanding its product portfolio from two to seven differentiated offerings, enhancing its market position and sales potential.
TriSalus Life Sciences Inc (TLSI) is investing in foundational clinical studies to validate its PEDD platform, which is expected to fuel growth in 2027 and beyond.

Negative

The company did not meet its timeline for releasing updated clinical data for the Nela Tolemad program, delaying it to the second half of 2026.
Despite strong revenue growth, TriSalus Life Sciences Inc (TLSI) reported a net operating loss of $3.3 million for the quarter.
The company is not providing specific guidance on cash flow break-even or adjusted EBITDA break-even, indicating uncertainty in financial projections.
General and administrative expenses increased by $3.5 million for the year, partly due to a one-time charge related to stock-based compensation.
The basic and diluted loss per share increased to $1.84 from $1.31 in the previous year, primarily due to the conversion of preferred stock to common stock.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TLSI.OQ - TriSalus Life Sciences Inc
Q4 2025 TriSalus Life Sciences Inc Earnings Call
Mar 05, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
2 Good day and welcome to the TriSalis Life Sciences 4th quarter 2025 earnings call.

At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. So withdraw your question, press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Mr. Jeremy Pfeffer, investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.